March 28th 2024
Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
UV light relieves itch of multiple etiologies
June 1st 2002Mechanism action UVB treatment isinactivation of pruritogenic substancesNewOrleans - UV light therapy has been used to treat a variety of pruriticconditions, although there is a lack of definitive data regarding the efficacyof the therapeutic modality in some of the disorders for which it has beentried, Henry W. Lim, M.D., said at the annual meeting of the American Academyof Dermatology.
Pimecrolimus, tacrolimus keep in check pediatric AD
June 1st 2002New Orleans - New long-term data with the topical immunomodulator tacrolimus(Protopic) and the skin-selective inflammatory cytokine inhibitor pimecrolimus(Elidel) demonstrate efficacy as maintenance therapies in the treatmentof atopic dermatitis in children. Data with pimecrolimus show safety andefficacy for as long as 26 weeks in infants as young as three months, LawrenceEichenfield, M.D., said at the annual meeting of the American Academy ofDermatology.
Studies further condemn UVA reputation
May 1st 2002New Orleans - The role of UVA radiation in generating a number of diseases is now much better understood, Robert Bissonnette, M.D., said at the annual meeting of the American Academy of Dermatology. "If you go back 10 years, we knew a lot about UVB but little about UVA. Now, we know that it can cause skin cancer in animals," he said.
Lesion size, location dictate decision on pediatric surgery
April 1st 2002New Orleans - Timing is key for a successful outcome when performing dermatologic surgery in pediatric patients, and lesion size and location are the two most important variables factoring into the equation, Annette M. Wagner, M.D., said at the annual meeting of the American Academy of Dermatology.
Systemic CD often an elusive diagnosis
April 1st 2002New Orleans - Systemic contact dermatitis may present with a variety of eczematous and noneczematous cutaneous reaction patterns and may be an overlooked diagnosis unless clinicians maintain an index of suspicion that systemic exposure to a contact allergen is driving the skin eruption, Donald V. Belsito, M.D., said at the annual meeting of the American Academy of Dermatology.